Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Collette

Showing results (21-30 of 155) with videos related to

Pageof 16
Sort By:
Journal of the National Cancer Institute|March 7, 2019
Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II DoseMaria-Athina Altzerinakou, Laurence Collette, Xavier Paoletti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Adjuvant radiotherapy after surgery for pathologically advanced prostate cancerTheodorus H Van der Kwast, Laurence Collette, Michel Bolla
European Urology|July 24, 2003
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)Laurence Collette, Theo M de Reijke, Fritz H Schröder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Clinical trial designs for predictive marker validation in cancer treatment trialsDaniel J Sargent, Barbara A Conley, Carmen Allegra, et al.
Journal of Biopharmaceutical Statistics|July 24, 2019
Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg designAnouk Neven, Murielle Mauer, Baktiar Hasan, et al.
The Lancet. Oncology|May 3, 2008
Palliative-care trials: how best to publish findings?Murielle E Mauer, Andrew Bottomley, Laurence Collette, et al.
European Urology|July 15, 2010
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic reviewPaul C M S Verhagen, Fritz H Schröder, Laurence Collette, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 28, 2020
Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trialsJulien Péron, Anouk Neven, Laurence Collette, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|March 4, 2011
BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001)Andrea Wittig, Sien-Yi Sheu-Grabellus, Laurence Collette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca PharmaceuticalsLaurence Collette, Tomasz Burzykowski, Kevin J Carroll, et al.
Pageof 16

Showing results (21-30 of 155) with videos related to

Sort By:
Pageof 16
Journal of the National Cancer Institute|March 7, 2019
Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II DoseMaria-Athina Altzerinakou, Laurence Collette, Xavier Paoletti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Adjuvant radiotherapy after surgery for pathologically advanced prostate cancerTheodorus H Van der Kwast, Laurence Collette, Michel Bolla
European Urology|July 24, 2003
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)Laurence Collette, Theo M de Reijke, Fritz H Schröder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Clinical trial designs for predictive marker validation in cancer treatment trialsDaniel J Sargent, Barbara A Conley, Carmen Allegra, et al.
Journal of Biopharmaceutical Statistics|July 24, 2019
Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg designAnouk Neven, Murielle Mauer, Baktiar Hasan, et al.
The Lancet. Oncology|May 3, 2008
Palliative-care trials: how best to publish findings?Murielle E Mauer, Andrew Bottomley, Laurence Collette, et al.
European Urology|July 15, 2010
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic reviewPaul C M S Verhagen, Fritz H Schröder, Laurence Collette, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 28, 2020
Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trialsJulien Péron, Anouk Neven, Laurence Collette, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|March 4, 2011
BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001)Andrea Wittig, Sien-Yi Sheu-Grabellus, Laurence Collette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca PharmaceuticalsLaurence Collette, Tomasz Burzykowski, Kevin J Carroll, et al.
Pageof 16